Therapeutic effect and influence of rosuvastatin on IL-35 and NF-κB levels in patients with coronary heart disease
10.3969/j.issn.1008-0074.2016.02.20
- VernacularTitle:瑞舒伐他汀对冠心病患者的疗效及IL-35、NF-κB水平的影响
- Author:
Geping XU
;
Bo CUI
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Chemokines;
Rosuvastatin;
Atorvastatin
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2016;25(2):185-188
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe therapeutic effect and influence of rosuvastatin on levels of interleukin (IL)-35 and nu- clear factor-κB (NF-κB)in patients with coronary heart disease (CHD).Methods:A total of 85 CHD patients were randomly divided into rosuvastatin group (n=43,received rosuvastatin calcium therapy based on routine treatment)and atorvastatin group (n=42,received atorvastatin calcium therapy based on routine treatment),both groups were treated for eight weeks all.Cardiac index (CI),cardiac output (CO),left ventricular ejection fraction (LVEF),left ventricular end-diastolic dimension (LVEDd),serum levels of IL-35 and NF-κB,and total effective rate were measured and compared be- tween two groups before and after treatment.Results:Compared with before treatment,there were significant rise in CI, CO,LVEF and IL-35 level,and significant reductions in LVEDd and NF-κB level in both groups after treatment (P<0.05 or<0.01).Compared with atorvastatin group after treatment,there were significant rise in CI [(3.54±0.72)L· min-1 ·m-2 vs.(3.88±0.83)L·min-1 ·m-2 ],CO [(3.78±0.89)L/min vs.(4.94±0.96)L/min],LVEF [(56.20 ±9.71)% vs.(63.48±14.15)%]and serum IL-35 level [(96.26±24.33)pg/ml vs.(106.92±27.26)pg/ml],and sig- nificant reductions in LVEDd [(4.71±0.89)cm vs.(4.36±0.75)cm]and NF-κB level [(21.51±5.01)ng/ml vs. (18.32± 5.17)ng/ml]in rosuvastatin group,P<0.05 all.Total effective rate of rosuvastatin group (95.35% vs. 76.19%)was significantly higher than that of atorvastatin group,P<0.05. Conclusion:Rosuvastatin possesses more sig- nificant therapeutic effect than that of atorvastatin on coronary heart disease,and its heart protection effect besides lipid lowering may be related to regulating levels of interleukin-35 and nuclear factor-κB.
